Ulipristal acetate versus leuprolide acetate for uterine fibroids

New England Journal of Medicine

Volumn 366, Issue 5, 2012, Pages 421-432

  Donnez, Jacques ^a   Tomaszewski, Janusz ^b   Vázquez, Francisco ^e   Bouchard, Philippe ^f   Lemieszczuk, Boguslav ^c   Baró, Francesco ^g   Nouri, Kazem ^h   Selvaggi, Luigi ⁱ   Sodowski, Krzysztof ^d   Bestel, Elke ^j   Terrill, Paul ^k   Osterloh, Ian ^l   Loumaye, Ernest ^j  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Prywatna Klinika Polozniczo Ginekologiczna   (Poland)

^c Gabinet Lekarski Specjalistyczny Sonus   (Poland)

^d Centrum Medyczne Krzysztof Sodowski   (Poland)

^e Clinica Ginecologica El Centro de Estudios de Obstetricia y Ginecología Asociado   (Spain)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY OF BARI   (Italy)

^j Preglem   (Switzerland)

^k MDSL International   (United Kingdom)

^l OsterMed   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LEUPRORELIN; ULIPRISTAL;

ABDOMINAL PAIN; ACNE; ADULT; AMENORRHEA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD PRESSURE; BREAST TENDERNESS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENDOMETRIUM HYPERPLASIA; FATIGUE; FEMALE; HEART RATE; HOT FLUSH; HUMAN; INFLUENZA; INJECTION PAIN; INSOMNIA; LUNG INFECTION; MAJOR CLINICAL STUDY; MASTALGIA; NAUSEA; PARALLEL DESIGN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYMPTOMATOLOGY; THYROID CANCER; THYROTROPIN BLOOD LEVEL; TREATMENT OUTCOME; UTERUS BLEEDING; UTERUS MYOMA;

EID: 84856563732     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1103180     Document Type: Article

References (38)

1. Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002;17:1424-30. (Pubitemid 34661784)
2. Viswanathan M, Hartmann K, McKoy N, et al. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep) 2007:1-122.
3. Hoekstra AV, Sefton EC, Berry E, et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab 2009;94:1768-74.
4. Yin P, Lin Z, Reierstad S, et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010;70:1722-30.
5. Scialli AR, Jestila KJ. Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. Fertil Steril 1995;64:313-20.
6. Kim JJ, Sefton EC. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 2011 June 6 (Epub ahead of print).
7. Sayed GH, Zakhera MS, El-Nashar SA, Shaaban MM. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int J Gynaecol Obstet 2011;112:126-30.
8. Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum Reprod 1999;14:2844-50. (Pubitemid 29520705)
9. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001:CD000547.
10. Stovall TG, Muneyyirci-Delale O, Summit RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Obstet Gynecol 1995;86:65-71.
11. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006;108:1381-7. (Pubitemid 44901011)
12. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 2009;21:318-24.
13. Attardi BJ, Burgenson J, Hild SA, Reel JR, Blye RP. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 2002;188:111-23. (Pubitemid 34242671)
14. Attardi BJ, Burgenson J, Hild SA, Reel JR. In vitro antiprogestational/ antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol 2004; 88:277-88. (Pubitemid 38553759)
15. Gainer EE, Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids 2003; 68:1005-11. (Pubitemid 37532425)
16. Yoshida S, Ohara N, Xu Q, et al. Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010;28:260-73.
17. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008;21:591-8. (Pubitemid 351589653)
18. U.S. Food and Drug Administration. Guidance for industry: estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation: draft guidance (http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/ UCM135338.pdf).
19. Ioffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 2009;22: 450-9.
20. Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111: 1129-36. (Pubitemid 351620347)
21. Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011; 95(2):767.e1-2-772.e1- 2.
22. Higham JM, O'Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990;97:734-9. (Pubitemid 20263124)
23. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss. Obstet Gynecol 1995;85:977-82.
24. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987;30:191-7. (Pubitemid 18029372)
25. Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol 2002;99:290-300. (Pubitemid 34114003)
26. Chen W, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006;91:1296-304.
27. Luo X, Yin P, Coon VJS, Cheng YH, Wiehle RD, Bulun SE. The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril 2010;93:2668-73.
28. Maruo T, Ohara N, Matsuo H, et al. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception 2007;75:Suppl:S99-S103. (Pubitemid 46770714)
29. Xu Q, Takekida S, Ohara N, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5′-diphosphate- ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005;90: 953-61. (Pubitemid 40279221)
30. Xu Q, Ohara N, Liu J, et al. Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells. Am J Physiol Endocrinol Metab 2007; 293(4):E1002-E1011. (Pubitemid 47535831)
31. Sasaki H, Ohara N, Xu Q, et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2007; 92:616-23.
32. Wang J, Ohara N, Wang Z, et al. A novel selective progesterone receptor modulator asoprisnil (J867) down-regulates the expression of EGF, IGF-I, TGFbeta3 and their receptors in cultured uterine leiomyoma cells. Hum Reprod 2006;21:1869-77. (Pubitemid 44028263)
33. Xu Q, Ohara N, Chen W, et al. Progesterone receptor modulator CDB-2914 downregulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 2006;21:2408-16. (Pubitemid 44530620)
34. Friedman AJ, Hoffman DI, Comite F, et al. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. Obstet Gynecol 1991;77:720-5.
35. Carr BR, Marshburn PB, Weatherall PT, et al. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-23. (Pubitemid 23155439)
36. Cirkel U, Ochs H, Schneider HP, et al. Experience with leuprorelin acetate depot in the treatment of fibroids: a German multicentre study. Clin Ther 1992;Suppl: 37-50.
37. Coddington CC, Brzyski R, Hansen KA, Corley DR, McIntyre-Seltman K, Jones HW Jr. Short term treatment with leuprolide acetate is a successful adjunct to surgical therapy of leiomyomas of the uterus. Surg Gynecol Obstet 1992;175:57-63.
38. Watanabe Y, Nakamura G, Matsuguchi H, Nozaki M, Sano M, Nakano H. Efficacy of a low-dose leuprolide acetate depot in the treatment of uterine leiomyomata in Japanese women. Fertil Steril 1992; 58:66-71.